Article
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
All News
Article
The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty.
Article
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.
Dr. Rachel Tate
Tweet
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Eric Dein
Tweet
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Meral K. El Ramahi, MD
Tweet
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews
Eric Dein
Tweet
#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow
Nelly ZIADE 🍀
Tweet
Do patients with #SpA have a different phenotype if they have "root joint disease"?
Find out at the #EULAR2021 Poster Tour #POS0239
or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9
Janet Pope
Tweet
@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?
Robert B Chao, MD
Tweet
Don’t forget to use imaging that you already have!
CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis
⭐️60/301 had sacroilitis on CT
⭐️11/60 had AxSpA
⭐️3/60 previously undiagnosed axSpA
Abs#POS0035
#EULAR2021 @RheumNow
Meral K. El Ramahi, MD
Tweet
➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi
➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l
#EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Robert B Chao, MD
Tweet
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus
⭐️⬇️AS activity w/ or w/o MRI sacroilitis
Abs#OP0142
#EULAR2021 @RheumNow
k dao
Tweet
Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
Robert B Chao, MD
Tweet
Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks!
⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes
⭐️no significant changes in spine fat, bone erosion or new bone formation
Abs#OP0141
#EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
Robert B Chao, MD
Tweet
Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow
How do you help pts manage fatigue?
Meral K. El Ramahi, MD
Tweet
➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID.
➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz
OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
Meral K. El Ramahi, MD
Tweet
Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?
⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID
⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w
🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA.
OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
Nelly ZIADE 🍀
Tweet
Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik
⭐️Individual socioeconomic factors associated with poorer outcomes
⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw
